Iridoids

Other Names

Acetal derivatives of iridodialBis-iridoidsBis-secoiridoidsBisiridoidsBitter monoterpene glycosidesCyclopentan-[c]-pyran monoterpenoidsCyclopentane monoterpenesCyclopentane pyran monoterpenesCyclopentanoid monoterpenesCyclopentanoid terpenesCyclopentanopyran monoterpenoidsCyclopenta[c]pyran monoterpenoidsDimer iridoidsGlycosidic iridoidsIridane monoterpenesIridane skeleton compoundsIridodial derivativesIridoidIridoid aglyconesIridoid glucosidesIridoid glycosidesIridoid monoterpenesMonoterpene glycosidesNon-glycosidic iridoidsNonglycosylated iridoidsPlant bitter glycosidesSecoiridoid glycosidesSecoiridoidsSimple iridoids

Synopsis

Iridoids: A Comprehensive Reference

1. Identity, Chemical Nature, and Classification

Iridoids are a diverse class of plant food monoterpenoids characterized by a cyclopentane-fused pyran ring structure, exhibiting extensive structural diversity and functional versatility. More precisely, iridoid is a special class of monoterpenoids whose basic skeleton is the acetal derivative of antinodilaldehyde with a bicyclic H-5/H-9β, β-cis-fused cyclopentan pyran ring. Iridoids belong to monoterpenoids, which are acetal derivatives of iridodial. Because of the unstable nature of its C1-OH group, iridoids often react with sugar to form glycosides.

Based on structure, iridoids can be divided into four groups: iridoid glycosides, secoiridoid glycosides, non-glycosidic iridoids, and bis-iridoids. Iridoids have hemiacetal hydroxyl groups and are active in nature; they are mostly in the form of glycosides and are combined with glucose at the C-1 hydroxyl group. Secoiridoids have many structural differences compared with the iridoid glycosides. Compounds from the secoiridoid class are widely distributed in Gentianaceae, Nymphaeaceae, Caprifoliaceae, and Oleaceae, and are more common in Gentianaceae and Swertia. The C7–C8 in secoiridoids in the parent nucleus is usually broken to form a cleavage ring.

Iridoids exhibit considerable structural diversity, which is primarily attributed to the enzymatic modifications of their core cyclopentanopyran scaffold. Structure–activity relationship analysis suggests that glycosyl, ester, and epoxy groups are essential pharmacophores for their bioactivity.

1.1 Major Individual Iridoid Compounds

Aucubin — an iridoid glycoside found widely across medicinal plants. Aucubin, which is frequently found as a natural constituent of many traditional medicinal plants, is used in the alleviation of chronic allergic inflammatory disease.
Catalpol — Catalpol, known for its neuroprotective activity, is the major constituent of the roots of Rehmannia glutinosa, which are traditionally used for the treatment of auditory diseases such as tinnitus.
Geniposide — Geniposide is a main iridoid glucoside of Gardenia jasminoides, at 56.2 mg/500 mg extract. Gardenia fruits are used for the treatment of anti-inflammatory, hepatic, and gall bladder diseases.
Genipin — Genipin is a non-glycosidic iridoid isolated mainly from the fruits of Gardenia jasminoides and Genipa americana. It is the active ingredient in extracts from these plants, responsible for their anti-inflammatory and hepatoprotective effects.
Harpagoside — Harpagoside is the major iridoid glycoside (0.5–1.6%) in Harpagophytum procumbens, an herbal medicine for rheumatologic conditions.
Loganin, morroniside, sweroside — secoiridoid and iridoid glycosides found in Cornus officinalis and related species. The extract of C. officinalis is composed of organic acids, polysaccharides, saponins, and iridoids such as oleanolic acid, ursolic acid, morroniside, loganin, sweroside, and cornuside. Cornus officinalis is a traditional Oriental medicine credited with curing inflammatory diseases and invigorating blood circulation.
Oleuropein — a secoiridoid prominent in olive (Olea europaea). One well-studied source is the olive tree, particularly its leaves. Olive leaf extracts are rich in the secoiridoid oleuropein, which is present at much higher concentrations in the leaves than in the fruit or olive oil.
Valepotriates — Valeriana officinalis (valerian) is an herb used for its sedative properties, partially attributed to iridoids called valepotriates. Valepotriates are unique, highly unstable triesters of iridoid-monoterpenes.
Asperuloside / Deacetylasperulosidic acid — prominent in noni (Morinda citrifolia). Another significant source is the noni fruit, a traditional food and medicine in Polynesian cultures. The fruit and leaves of noni contain notable amounts of iridoids, including deacetylasperulosidic acid and asperulosidic acid, which contribute to the fruit's distinctively bitter flavor.

2. Natural Distribution and Botanical Sources

Iridoids represent a large group of cyclopenta[c]pyran monoterpenoids that occur widespread in nature, mainly in dicotyledonous plant families like Apocynaceae, Scrophulariaceae, Diervillaceae, Lamiaceae, Loganiaceae, and Rubiaceae. Their basic skeleton is a bicyclic cyclopentan pyran ring. They are often found in Valerianaceae, Rubiaceae, Scrophulariaceae, and Labiaceae families, and have various biological activities, such as anti-inflammatory, hypoglycemic, and neuroprotective.

Iridoids are secondary metabolites produced by plants and some animals as a defense mechanism against animals and insects. They are cyclopenta[c]pyrane-containing monoterpenoids presenting various pharmacological effects, and have been used traditionally in Ayurveda and folk medicine.

2.1 Dietary and Food Sources

Iridoids are scarce in edible fruits and are not perceived as important phytocompounds of dietary fruits and food products. However, they do occur in some common edible fruits — olive, noni, berries — and a few less-common but unique fruits — Japanese cornel, cornelian cherry, kousa dogwood, haskap berry, and guelder rose.

Quantified iridoid concentrations in food sources have been documented in recent literature. In noni fruit (Morinda citrifolia) juice, the total iridoid content, primarily deacetyloasperulosidic acid and asperulosidic acid, is about 166 mg/100 mL. Virgin olive oil contains 93 mg/100 mL of oleuropein, 8.5 mg/100 mL of oleuropein aglycone, and 28 mg/100 mL of ligstroside. Bilberry (Vaccinium myrtillus) juice provides 206 mg/100 mL of total iridoids, whereas bilberry wine contains a lower concentration of 64.4 mg/L. Dried Fructus corni fruit displays the highest iridoid content among the listed products, ranging from 2610 to 3000 mg/100 g. Processed products such as cornelian cherry (Cornus mas) jam contain 48–128 mg/100 g of iridoids, including loganic acid and cornuside.

3. Traditional and Historical Use

As one of the active components used in natural medicine and traditional Chinese medicine, iridoid compounds have many biological effects such as liver protection, anti-inflammatory, and anti-tumor effects. Specific iridoid-bearing plants have a long and well-documented history of use across multiple cultures:

3.1 Traditional Chinese Medicine (TCM)

Use of Cornus officinalis (Shan Zhu Yu) was first recorded in Shen Nong's Materia Medica about 2000 years ago in China. Cornel iridoid glycoside (CIG) is a main component extracted from C. officinalis, which also contains morroniside, loganin, sweroside, and cornuside. Cornus officinalis is a traditional Oriental medicine credited with curing inflammatory diseases and invigorating blood circulation.

Radix Rehmanniae (RR), a famous traditional Chinese medicine widely employed in nourishing Yin and invigorating the kidney, has three common processing forms in clinical practice: fresh Radix Rehmanniae (FRR), raw Radix Rehmanniae (RRR), and processed Radix Rehmanniae (PRR). Catalpol is its chief iridoid constituent.

The dried fruit of Gardenia jasminoides Ellis is widely used as a traditional medicine and health food. This fruit is used for the treatment of various diseases, including diarrhea, headache, and jaundice. It is also used as a food ingredient and dietary supplement mixed with health foods or tea.

3.2 African Traditional Medicine

Devil's claw (Harpagophytum procumbens), which contains the iridoid glycoside harpagoside, has been used in African folk medicine for centuries to alleviate pain and treat inflammatory conditions.

3.3 Ayurveda and Other Folk Systems

Iridoids are cyclopenta[c]pyrane-containing monoterpenoids that have been used traditionally in Ayurveda and folk medicine. Plumeria species are well known to have various pharmacological properties employed in traditional medicine for diarrhea, gonorrhea, syphilis, fever, cough, tracheitis, infective hepatitis, and bronchitis. These pharmacological properties are due to the presence of certain secondary metabolites such as iridoids, alkaloids, flavonoids, terpenoids, tannins, and steroids.

3.4 Mediterranean Traditions

Verbascum phlomoides is a member of the Scrophulariaceae family, traditionally employed across Eurasia for respiratory ailments such as bronchitis, asthma, and spasmodic cough. Mediterranean use of olive products, now known to be rich in oleuropein, is among the most ancient dietary traditions in human history.

4. Key Constituents and Established Mechanisms of Action

4.1 Anti-Inflammatory Mechanisms

Iridoid compounds were found to modulate critical signaling pathways, including NF-κB, NLRP3 inflammasome, MAPK, and JAK-STAT, thereby suppressing key inflammatory cytokines such as TNF-α, IL-1β, and IL-6, while also activating antioxidant defenses.

Many iridoid glycosides have been recognized as potent modulators of the NF-κB signaling pathway, producing anti-inflammatory, antioxidant, and cytoprotective effects, mostly by hindering the process of NF-κB nuclear translocation.

With regard to harpagoside specifically: harpagoside, one of the key iridoids found in Scrophularia nodosa, has demonstrated the capacity to inhibit LPS-induced mRNA levels and expression of COX-2, as well as inducible iNOS in HepG2 cells. These inhibitory effects correlate with the upstream suppression of NF-κB activation, as pretreatment of cells with this phytochemical blocked the degradation of the inhibitory subunit IκB-α and the nuclear translocation of NF-κB. Furthermore, harpagoside dose-dependently inhibited LPS-induced NF-κB activity in a macrophage population, confirming its ability to block pro-inflammatory gene trans-activation.

Catalposide has been reported to inhibit the production of TNF-α, IL-1β, and IL-6, as well as the activation of NF-κB in LPS-activated RAW 264.7 macrophages. In addition, it inhibited the expression of these genes and the nuclear translocation of the p65 subunit of NF-κB. A possible mechanism of action is that catalposide inhibits the binding of LPS to RAW 264.7 cells.

According to current research, genipin, geniposide, and monotropein are the most researched iridoids from Rubiaceae that reduce inflammation. These iridoids primarily act by attenuating inflammatory cytokines and mediators via inhibition of the NF-κB signalling pathway in various disease models.

4.2 Neuroprotective Mechanisms

All the available data suggest that the iridoids are a class of natural lipophile compounds with the properties of endogenous neurotrophic factors, which could be considered as potential leads for the treatment of neurodegenerative diseases.

Iridoids exert antidepressant effects by elevating monoamine neurotransmitters, reducing pro-inflammatory factors, inhibiting hypothalamic-pituitary-adrenal (HPA) axis hyperactivity, increasing brain-derived neurotrophic factor (BDNF) and its receptors, and elevating intestinal microbial abundance.

Generally, compared with their carbohydrates, aglycones and acylated iridoids are more likely to passively diffuse through the blood-brain barrier (BBB). Numerous studies revealed that geniposide, oleuropein, catalpol, loganin, and picroside II can cross the BBB and enter the CNS to exert a neuroprotective role.

4.3 Hepatoprotective Mechanisms

Iridoids exhibit remarkable hepatoprotective effects, making them potential candidates for preventing and treating liver-related disorders. Iridoids such as geniposide, aucubin, and catalpol have been shown to protect hepatocytes from damage caused by oxidative stress, inflammation, and toxic insults. Geniposide mitigates liver injury by suppressing inflammatory pathways, including NF-κB activation, and enhancing antioxidant defenses through Nrf2-mediated signaling. Similarly, aucubin has demonstrated protective effects in alcoholic liver disease models by reducing lipid peroxidation and promoting mitochondrial function.

4.4 Antioxidant Mechanisms

The antioxidant properties of iridoids such as catalpol, swertiamarin, geniposide, loganin, and oleuropein have been established in various in vitro and in vivo experimental models, revealing their capacity to diminish oxidative damage associated with chronic diseases such as cardiovascular diseases and type 2 diabetes.

Loganic acid, the most abundant iridoid of Lonicera caerulea, scavenges free radicals and amplifies the function of endogenous antioxidant enzymes, such as superoxide dismutase (SOD) and catalase (CAT).

Many iridoids have shown promise in countering both oxidative stress and inflammation. In an in vitro model of oxidative stress, catalpol demonstrated significant antioxidant activity in human umbilical vein endothelial cells (HUVECs) by reducing intracellular reactive oxygen species (ROS) levels induced by hydrogen peroxide (H₂O₂) exposure.

4.5 GLP-1 Receptor Agonism (Metabolic Mechanisms)

Emerging preclinical evidence indicates that several iridoid glycosides, such as geniposide, shanzhiside methylester, 8-O-acetyl shanzhiside methyl ester, morroniside, and catalpol, may act as direct small-molecule agonists of the GLP-1 receptor (GLP-1R). This receptor plays a central role in glucose regulation, insulin secretion, and appetite control.

4.6 Pro-Drug Character and Intestinal Metabolism

The hypothesis that iridoid glycosides and acetal esters can best be considered as pro-drugs, and that corresponding hemiacetals and compounds derived from them carry the pharmacophores, has been discussed in the scientific literature. Most glycosides share similar properties such as strong modifiability and rapid absorption; hence, they are popular sources of lead compounds.

Studies have found that intestinal bacteria can convert geniposide to genipin. After sulfatase hydrolysis of plasma samples, many genipins appeared, indicating that genipin sulfate is the main metabolite of genipin. Both oral administration and injection of genipin could quickly detect the presence of genipin sulfate, indicating that genipin sulfate is produced when passing through the intestines and liver.

4.7 Anticancer Mechanisms

Results demonstrate that hydrolyzed iridoids (H-iridoids), such as H-geniposide, inhibit constitutive STAT3 activation through the suppression of constitutive JAK1 and c-Src activation, which makes H-iridoids a potentially effective suppressor of tumor cell survival and proliferation. However, further clinical studies are needed with H-iridoids alone and in combination with standard chemotherapeutics to demonstrate their potential applications.

Because of the chemically active hemiacetal structure in their common basic skeleton, secoiridoids have a wide range of biological activities, such as neuroprotective, anti-inflammatory, antidiabetic, hepatoprotective, and antinociceptive activities. Phenolic secoiridoids can also act against multiple molecular targets involved in human tumorigenesis, making them potentially valuable precursors for antitumor drug development.

5. Scientific Evidence by Area of Use

5.1 Musculoskeletal Pain and Osteoarthritis (Strongest Clinical Evidence)

The most robust clinical evidence for iridoid-containing preparations concerns Harpagophytum procumbens (devil's claw), whose active iridoid is harpagoside. Twelve trials were included in one systematic review, with six investigating osteoarthritis (two were identical trials), four low back pain, and three mixed-pain conditions.

Two high-quality trials examining the effects of Harpagophytum procumbens (Devil's Claw) found strong evidence that daily doses standardized to 50 mg or 100 mg harpagoside were better than placebo for short-term improvements in pain and rescue medication. Another high-quality trial demonstrated relative equivalence to 12.5 mg per day of rofecoxib (Vioxx).

There is moderate evidence of effectiveness for: (1) the use of a Harpagophytum powder at 60 mg harpagoside in the treatment of osteoarthritis of the spine, hip, and knee; (2) the use of an aqueous Harpagophytum extract at a daily dose of 100 mg harpagoside in the treatment of acute exacerbations of chronic non-specific low back pain; and (3) the use of an aqueous extract of Harpagophytum procumbens at 60 mg harpagoside being non-inferior to 12.5 mg rofecoxib per day for chronic non-specific low back pain (NSLBP) in the short term. Strong evidence exists for the use of an aqueous Harpagophytum extract at a daily dose equivalent of 50 mg harpagoside in the treatment of acute exacerbations of chronic NSLBP.

Studies offering preparations with 50–60 mg harpagoside in the daily dosage are of better quality and provide more reliable evidence on efficacy than a proprietary ethanol extract with half the amount of harpagoside per day. However, confirmatory studies are required for all extracts before they can gain a place in treatment guidelines.

In a randomized, double-blind trial of 197 patients with chronic back pain, two daily doses of harpagoside-standardized Harpagophytum extract WS 1531 (600 mg and 1200 mg, containing 50 mg and 100 mg harpagoside, respectively) were compared with placebo over 4 weeks.

Evidence strength: Moderate-to-strong for short-term pain reduction in low back pain; limited for osteoarthritis of the hip and knee; statistical pooling was not possible due to clinical heterogeneity across trials. Statistical pooling was not possible because of a lack of adequate data and clinical heterogeneity.

5.2 Neuropathic Pain (Preclinical)

Iridoid glycosides including loganin, catalpol, geniposide, gardenoside, shanzhiside methyl ester, 8-O-acetyl-shanzhiside methyl ester, picroside II, and aucubin, and secoiridoid glycosides such as morroniside, gentiopicroside, and oleuropein consistently reverse mechanical allodynia and thermal hyperalgesia in rodent models, with ED50 values ranging from 5 μg (intrathecal) to 130–250 mg/kg (oral), without tolerance after repeated dosing.

The above studies collectively demonstrated that iridoid glycosides and related natural compounds exhibit significant analgesic efficacy in standardized neuropathic pain models. These iridoid glycosides effectively ameliorated both mechanical and thermal hypersensitivity, often in a dose-dependent manner, and their effects were sustained over repeated administrations without apparent tolerance.

Evidence strength: Preclinical only (animal models). No adequately powered human clinical trials for neuropathic pain have been identified in the peer-reviewed literature for individual iridoids.

5.3 Neurological and Mood Disorders (Preclinical)

Plant iridoids (catalpol, geniposide, loganin) and secoiridoids (morroniside, gentiopicroside, oleuropein, swertiamarin) all showed significant improvement effects on depression in experimental models.

Studies found that oral catalpol, aucubin, geniposide, harpagoside, loganin, and globularifolin can reduce stress and depression by diminishing anhedonia, enhancing corticosterone and BDNF, and decreasing COX-2 levels.

For example, catalpol, an iridoid glycoside extracted from the roots of Rehmannia glutinosa (Scrophulariaceae), improves cognitive impairment and therefore treats depression. Geniposide, as the largest quantity of iridoid chemical in Gardenia jasminoides Ellis (Rubiaceae), is one of the most effective components in the treatment of depression in experimental settings.

Further detailed studies on the pharmacokinetics, bioavailability, and key molecular targets of iridoids are required in future research, ultimately to provide improvements to current antidepressant medications.

Evidence strength: Predominantly preclinical (cell cultures and animal models). Human clinical trial evidence for iridoids specifically targeting neurological or mood disorders is currently lacking.

5.4 Hepatoprotection (Preclinical)

Iridoids exhibit remarkable hepatoprotective effects, making them potential candidates for preventing and treating liver-related disorders. Iridoids such as geniposide, aucubin, and catalpol have been shown to protect hepatocytes from damage caused by oxidative stress, inflammation, and toxic insults. Geniposide mitigates liver injury by suppressing inflammatory pathways, including NF-κB activation, and enhancing antioxidant defenses through Nrf2-mediated signaling. Similarly, aucubin has demonstrated protective effects in alcoholic liver disease models by reducing lipid peroxidation and promoting mitochondrial function. These observations suggest that iridoids can effectively mitigate liver damage and promote hepatic function, although clinical trials are required to verify their safety and efficacy in humans.

A total of 63 hepatoprotective iridoids were found in a review of scientific databases, with aucubin, catalpol, and picroliv (a mixture of two iridoids) being the target of a high number of studies, which evince their protective activity.

Evidence strength: Preclinical (in vitro and animal model evidence). Clinical trials in humans are required, as explicitly noted by reviewers.

5.5 Metabolic Disease and Diabetes (Preclinical to Early Clinical)

Loganic acid has been associated with glycation inhibition, which is crucial in preventing diabetes-related complications. Additionally, cornuside and cornin contribute to glycemic control and metabolic protection, supporting their potential as natural agents in diabetes management.

Emerging preclinical evidence indicates that several iridoid glycosides — geniposide, shanzhiside methylester, 8-O-acetyl shanzhiside methyl ester, morroniside, and catalpol — may act as direct small-molecule agonists of the GLP-1 receptor, which plays a central role in glucose regulation, insulin secretion, and appetite control.

A limited number of clinical trials have demonstrated that iridoid-rich extracts can improve biomarkers of oxidative stress, inflammation, and metabolic health in patients with chronic conditions.

Evidence strength: Predominantly preclinical. The GLP-1R agonism data come from cell and animal studies. A limited number of clinical trials with iridoid-rich extracts have reported metabolic biomarker improvements, but large, well-powered, iridoid-specific clinical trials are still lacking.

5.6 Inflammation and Oxidative Stress (Preclinical to Limited Clinical)

Documented biological activities of iridoids include anti-inflammatory, antioxidant, immunomodulatory, antifibrotic, organoprotective, antibacterial, antiviral, analgesic, and metabolic effects.

Asperuloside (ASP) and asperulosidic acid (ASPA) significantly decreased the production of nitric oxide (NO), prostaglandin E₂ (PGE₂), TNF-α, and IL-6, in parallel with the inhibition of iNOS, COX-2, TNF-α, and IL-6 mRNA expression in LPS-induced RAW 264.7 cells.

A related iridoid-rich species (Scrophularia striata) showed efficacy in a randomized trial for chronic periodontitis, outperforming standard mouthwash in improving plaque index, pocket depth, and bleeding on probing.

To develop an alternative therapeutic agent from iridoids, more studies are needed to elucidate the effects and mechanism of action of iridoids in a wide variety of experimental models as well as in clinical studies pertaining to inflammation-related diseases.

5.7 Cancer (Preclinical)

Two iridoids, aucubin and geniposide, were found to cause DNA to selectively inhibit topoisomerase I without interfering with topoisomerase II.

Iridoid glycosides — aucubin, scandoside methyl ester, geniposide, loganin, sweroside, gardenoside, and gentiopicroside — were investigated for their anticancer properties in a leukemia model. All of the iridoids demonstrated no anticancer activity. However, the aglycones of the iridoids, especially aucubin and scandoside methyl ester, had significant anticancer activity against leukemia P388, with maximum total/control values of 162% and 160%, respectively, at 100 mg/kg.

In several in vitro tests, genipin's anti-proliferative activity against tumor cell lines has been demonstrated, and due to its ability to specifically inhibit the UCP2 protein and inhibit STAT3 activation, a significant increase in the cytotoxicity of several anticancer drugs was observed in co-treatment with genipin.

Evidence strength: Entirely preclinical (in vitro and animal studies). No human clinical trials for iridoids in cancer treatment have been identified. The glycoside forms of many iridoids may require hydrolysis to their aglycone forms to exert anticancer activity.

6. Body Systems and Health Areas Associated with Iridoids

Musculoskeletal system: Analgesic and anti-inflammatory actions, particularly harpagoside in joint and back pain (clinical evidence available).
Nervous system: Neuroprotection, antidepressant effects, analgesic activity in neuropathic pain models, potential role in neurodegenerative conditions (preclinical). These metabolites have been shown to have neuroprotective, hepatoprotective, anti-inflammatory, antitumor, hypoglycemic, and hypolipidemic activities.
Hepatic system: Protection of hepatocytes from oxidative, inflammatory, and toxic damage (preclinical).
Metabolic and endocrine system: Blood glucose modulation, GLP-1 receptor interactions, glycation inhibition (preclinical to very early clinical).
Cardiovascular system: Iridoids exhibit a wide range of bioactivity, such as neuroprotective, anti-inflammatory, immunomodulatory, hepatoprotective, and cardioprotective effects.
Immune system: Immunomodulatory and immunostimulant effects documented in cell culture and animal models.
Gastrointestinal system: Choleretic (bile-stimulating) and antispasmodic properties. Anticancer, antioxidant, antimicrobial, hypoglycaemic, hypolipidemic, choleretic, antispasmodic, and purgative properties were also reported.
Integumentary/oral system: Anti-inflammatory applications in periodontitis (limited clinical evidence).

7. Dosage Forms and Reported Dosages

Iridoids are consumed by humans through various food and medicinal plants, though concentrations vary significantly based on the plant part, cultivation, and processing. In supplemental and clinical contexts, the following dosage information has been reported in the peer-reviewed literature:

Harpagoside (from Harpagophytum procumbens): The dose of harpagoside in clinical studies ranged from less than 20 mg/day to 100 mg/day. Strong evidence was reported for the use of aqueous Harpagophytum (50 mg harpagoside) for exacerbations of chronic non-specific low back pain. Various preparations from Harpagophytum procumbens are used for the treatment of pain in the joints and lower back. Studies offering preparations with 50–60 mg harpagoside in the daily dosage are of better quality and provide more reliable evidence on efficacy.
Geniposide (from Gardenia jasminoides): Geniposide is a main iridoid glucoside of Gardenia jasminoides at 56.2 mg/500 mg extract as reported in one review. Clinical dosing ranges for isolated geniposide in humans have not been established in the identified literature.
Iridoids in animal models (neuropathic pain): ED50 values ranging from 5 μg (intrathecal) to 130–250 mg/kg (oral) have been reported across various iridoid glycosides in rodent models.
General preparations: Manufacturers often standardize products to a specific marker compound, such as oleuropein in olive leaf extracts, to ensure batch consistency. Iridoids possess considerable potential for industrial utilization in the food, pharmaceutical, and cosmetic industries due to their bioactive and multifunctional characteristics. The integration of iridoids into functional beverages, nutraceutical and nutritional supplements, and personal care formulations reveals emerging innovations.

8. Stability, Processing, and Bioavailability Considerations

Temperature, moisture, and light exposure affect iridoid stability. Recent advancements, including encapsulation and freeze-drying techniques, are increasingly employed to maintain iridoid content.

There has been less exploration of the dynamic variations in the characteristic constituents and degradation products of catalpol as a representative iridoid glycoside with the highest content in Radix Rehmanniae during the process from fresh to processed forms. Among iridoid glycosides, catalpol in particular exhibited a sharp decrease from raw to fully processed Radix Rehmanniae.

Advancements in drug delivery systems further improve the bioavailability and efficacy of iridoid-based pharmaceuticals.

9. Safety, Toxicology, and Drug Interaction Considerations

9.1 General Safety Profile

Iridoids are natural monoterpenoids, widely distributed in ornamental plants, herbs, and medicinal plants, but particularly in the green parts of plants. Their significance arises from diverse biological activities which have been well-documented and point to the natural-origin, non-toxic compounds for use in disease prevention and treatment. However, the general characterization of iridoids as "non-toxic" must be qualified in light of compound-specific and dose-specific findings.

9.2 Genipin Toxicity

When administered to rats at doses of 200 mg/kg, genipin was found to be highly toxic. Therefore, the dose of genipin should be properly formulated to ensure safety.

While many studies have demonstrated significant biological effects for genipin, there have been reports of possible hepatotoxicity. Therefore, an extremely important problem to be solved remains the determination of doses of this compound which could be effectively and at the same time safely used in the prevention and therapy of various diseases.

In zebrafish larval studies, it was found that genipin could induce cardiotoxicity, hepatotoxicity, and nephrotoxicity. After genipin treatment, suppression of antioxidant capacity and increase of oxidative stress were shown via triggered generation of ROS and MDA, and decreased activity of SOD.

Due to documented cases of hepatotoxicity, genipin and the blue pigment derived from it are being investigated for effective and safe therapeutic and non-drug use.

9.3 Geniposide Toxicity

A large body of pharmacological evidence has proved the various biological activities of geniposide, such as anti-inflammatory, anti-oxidative, anti-diabetic, neuroprotective, hepatoprotective, and cholagogic effects. However, there have been some research articles on its toxicity. Researchers aim to highlight these present issues and future perspectives to help develop and utilize this iridoid glycoside more efficiently and safely.

9.4 Valepotriates

When reports on the cytotoxicity of valtrate and didrovaltrate (valepotriates from valerian) appeared in 1981 and 1982 — although no side-effects of oral administration of valerian in man have been reported — attention switched to races and species of valerian, as well as selective preparations of the drug, which lacked these compounds.

9.5 Drug Interaction Concerns

There have been some research articles on the toxicity of geniposide in recent years. This information is included in comprehensive profiles of geniposide on its phytochemistry, pharmacology, pharmacokinetics, and toxicology in order to highlight present issues and future perspectives, as well as to help researchers develop and utilize this iridoid glycoside more efficiently and safely.

The iridoid glycosides derived from certain plants have been investigated at doses well below established toxicity thresholds, and their safety is further enhanced by traditional processing methods.

9.6 Strength of Evidence Summary for Safety

The overall evidence for iridoid safety is compound-specific and dose-dependent. Most food-derived iridoids consumed at levels normally found in diet are not reported to cause harm. Evidence from large-scale, well-controlled human studies remains limited. The diversity of iridoid glycosides and variation in plant sources complicate definitive conclusions on efficacy and safety. Genipin and high-dose geniposide have documented toxicity concerns requiring further dose-range characterization before therapeutic use can be fully established.

10. Industrial and Non-Therapeutic Applications

The importance of genipin has increased due to the possibility of using this iridoid as a biocompatible and low-cytotoxicity crosslinking agent in the manufacture of dressings, in tissue engineering, as a component of a drug carrier system, and in the production of food packaging. Genipin is also a substrate in the production of a blue pigment used as a food additive and fabric pigment.

Another interesting property of iridoid compounds is the production of colorants on reacting with amino acids or amine-containing reactants. They produce water-soluble dyes, among which genipin-producing blue dyes are widely studied and also used commercially.

References

Health Conditions

Health conditions that Iridoids may help support.

No conditions available.

Body Systems

Body systems that Iridoids may help support.

No body systems available.